Recent developments include clinical validation progress, reimbursement submissions, strategic partnerships, and capital raising activities.

• VolitionRx's Capture-Seq technology demonstrated over 95% detection of early-stage cancers, highlighting its diagnostic potential [N1].
• The company advanced its Nu.Q cancer assay program with a reimbursement submission in France, aiming to expand market access [N2].
• VolitionRx signed a co-marketing agreement with Hologic for the Nu.Q Discover service, supporting commercialization efforts [N11].
• Multiple analyst firms, including D. Boral Capital and HC Wainwright & Co., maintained buy recommendations on VolitionRx during late 2025, reflecting positive market sentiment [N3][N4][N5][N6][N7].
• In October 2025, VolitionRx priced a public offering of 11.55 million shares and warrants at $0.52 per set, raising capital to support research, development, and working capital needs [N8].

VolitionRx has demonstrated technological capabilities with its Capture-Seq platform showing over 95% detection of early-stage cancers, which could position it well in the growing market for non-invasive cancer diagnostics. The company's reimbursement submission in France and co-marketing agreement with Hologic indicate progress toward broader market access and commercialization. Continued clinical validation and strategic partnerships may enhance its commercial footprint and adoption.

The company reported significant net losses and limited liquidity, with a current ratio of 0.3 as of June 30, 2026, indicating potential financial constraints. It is subject to NYSE American listing compliance risks, with a plan to regain compliance by August 2027. The competitive landscape in cancer diagnostics is intense, and regulatory or reimbursement delays could impact commercialization. Execution risks include the ability to scale sales, secure reimbursement, and manage cash burn effectively.

VolitionRx's moat is based on its proprietary cancer detection technologies, including Capture-Seq and the Nu.Q assay platform, which target early-stage cancer detection with high sensitivity. The company's strategic partnerships and reimbursement efforts in key markets contribute to its competitive positioning. However, the biotechnology diagnostics field is competitive and rapidly evolving, requiring continuous innovation and regulatory progress to maintain differentiation.

• Financial Risk: The company has reported net losses and limited liquidity, with a current ratio below 1, indicating potential challenges in meeting short-term obligations.
• Listing Compliance Risk: VolitionRx is under a plan to regain compliance with NYSE American listing standards by August 2027, with potential delisting risk if compliance is not achieved.
• Regulatory and Reimbursement Risk: The company’s products require regulatory approvals and reimbursement agreements, which may face delays or denials impacting commercial success.
• Competitive Risk: The cancer diagnostics market is highly competitive with rapid technological advancements, posing risks to VolitionRx’s market share and differentiation.

• VolitionRx Limited is a Delaware corporation with its principal executive offices in Henderson, Nevada [S1].
• The company is listed on the NYSE American exchange under the ticker VNRX [S1].
• As of April 28, 2026, there were 8,087,955 shares of common stock issued and outstanding, adjusted for a one-for-twenty reverse stock split effective April 28, 2026 [S1].
• The company develops and commercializes cancer detection assays, including the Nu.Q product line and Capture-Seq technology for early-stage cancer detection [N1][N2].
• VolitionRx has entered into a co-marketing agreement with Hologic for the Nu.Q Discover service [N11].
• The company has submitted reimbursement submissions for its Nu.Q cancer assay program in France [N2].
• VolitionRx completed a public offering of 11.55 million shares and warrants at $0.52 per set in October 2025, raising net proceeds of approximately $4.1 million, with additional potential proceeds from warrant exercises [N8][S17].
• The company reported revenue of $398,657 for the quarter ended June 30, 2026, and a net loss of $7,326,047 for the same period [S2].
• Diluted earnings per share for Q2 2026 was -$0.85 [S2].
• As of June 30, 2026, VolitionRx had cash and cash equivalents of $2.8 million and current assets of approximately $4.1 million, with current liabilities of about $13.5 million, resulting in a current ratio of 0.3 and a cash ratio of 0.21 [S2].
• The company received a notice from NYSE American in early 2026 regarding non-compliance with listing standards related to stockholders' equity and submitted a plan to regain compliance by August 6, 2027, which was accepted by the exchange [S9][S11].
• The board of directors includes experienced executives with backgrounds in biotechnology, diagnostics, and healthcare innovation, including CEO Cameron Reynolds and non-executive Chairman Timothy Still [S1].
• VolitionRx has ongoing clinical studies and product commercialization efforts, with strategic partnerships and capital raising activities to support these initiatives [N1][N2][N8].
• There have been no material changes in the company's assessment of risk factors since the last annual report [S6].